Trial Outcomes & Findings for PF-06741086 Long-term Treatment in Severe Hemophilia (NCT NCT03363321)

Twenty-four participants were screened, of which, 4 failed at screening. All the 20 participants who met the eligibility criteria were assigned to the study treatment and were treated with marstacimab. Among 20 participants treated with marstacimab, 18 completed the study, and 2 discontinued from study due to withdrawal by participant, which were not related to safety.

PF-06741086 Long-term Treatment in Severe Hemophilia

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and non-serious AEs. TEAEs were AEs occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator. Grades 3 AEs were severe and undesirable adverse events. Grades 4 AEs were life threatening or disabling adverse events.

Following parameters were analyzed for laboratory examination: hematology, clinical chemistry, and urinalysis. The hematology parameters and pre-defined criteria included: neutrophils (10\^3/millimeter\[mm\]\^3) \<0.8\*lower limit of normal (LLN), and basophils (10\^3/mm\^3) \>1.2\*upper limit of normal (ULN). The clinical chemistry parameter and pre-defined criteria included: bilirubin (milligrams \[mg\]/decilitre \[dL\]) \>1.5 ULN, aspartate aminotransferase (units \[U\]/liter \[L\]) \>3.0 ULN, glucose (mg/dL) \>1.5\*ULN. The urinalysis parameter and pre-defined criteria included: urine glucose ≥1, ketones (scalar) ≥1, urine protein ≥1, urine hemoglobin (scalar) ≥1, and hyaline casts per low power field (/LPF). Participants met criteria at any time point were included.

Following parameters were analyzed for vital sign examination: blood pressure (BP), pulse rate (PR), temperature, respiration rate. Categorical vital signs: Temperature \>38.5 degree(s) Celsius (℃), Supine PR: \<40 or \>120 beats per minute (BPM), Systolic BP: \<90 mm Hg, \>=30 mm Hg change from baseline, Diastolic BP: \<50 mm Hg, \>=20 mm Hg change from baseline.

Baseline was defined as the average of triplicate ECG measurements collected prior to dosing on Day 1 in B7841003. Criteria for potentially clinically important changes in ECG were defined as: PR interval value \>=300 millisecond (msec); PR interval baseline \>200 msec and change \>=25%; PR interval baseline \<=200 msec and change \>=50%; QRS complex value \>=140 msec and change \>=50%; QTcF value \>=450 msec and change \>=30 msec. Only the number of participants meeting pre-defined criteria was reported below.

Physical examinations were conducted by a physician, trained physician's assistant, or nurse practitioner as acceptable according to local regulation. A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The limited or abbreviated physical examination was focused on general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. For measuring weight, a scale with appropriate range and resolution was used and must have been placed on a stable, flat surface. Participants removed shoes, bulky layers of clothing, and jackets so that only light clothing remains. They also removed the contents of their pockets and remain still during measurement of weight.

Injection site reactions included but were not limited to: erythema, induration, ecchymosis, pain and pruritus. Grade of severity was defined as follows: Mild: Transient or mild discomfort (\< 48 hours); no medical intervention/therapy required. Moderate: Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required. Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalizations possible.

The ABR was calculated as (\[number of bleeding events × 365.25\] / observed treatment period in days)